Abstract: In order to monitor the administration of medicament portions Ta in a reliable and simple manner, the invention provides a display device for a dispenser for medicament portions Ta, it being necessary to administer the medicament portions at regularly recurring reference administration times, and the display device comprising a display 1 and an electronic actuation means for the display, characterized in that the display comprises a first visualization means 30, 40 for displaying a first period of time between a first reference administration time and the current time, and the first reference administration time being distinguished in that the medicament portion has not been taken by the first reference administration time.

Abstract: In order to monitor the administration of medicament portions Ta in a reliable and simple manner, the invention provides a display device for a dispenser for medicament portions Ta, it being necessary to administer the medicament portions at regularly recurring reference administration times, and the display device comprising a display 1 and an electronic actuation means for the display, characterized in that the display comprises a first visualization means 30, 40 for displaying a first period of time between a first reference administration time and the current time, and the first reference administration time being distinguished in that the medicament portion has not been taken by the first reference administration time.

Abstract: In order to monitor the administration of medicament portions Ta in a reliable and simple manner, the invention provides a display device for a dispenser for medicament portions Ta, it being necessary to administer the medicament portions at regularly recurring reference administration times, and the display device comprising a display 1 and an electronic actuation means for the display, characterized in that the display comprises a first visualization means 30, 40 for displaying a first period of time between a first reference administration time and the current time, and the first reference administration time being distinguished in that the medicament portion has not been taken by the first reference administration time.

Abstract: The present invention relates to a coated pharmaceutical composition containing regorafenib, a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof and its process of preparation and its use for treating disorders.

Abstract: In order to monitor the administration of medicament portions Ta in a reliable and simple manner, the invention provides a display device for a dispenser for medicament portions Ta, it being necessary to administer the medicament portions at regularly recurring reference administration times, and the display device comprising a display 1 and an electronic actuation means for the display, characterized in that the display comprises a first visualization means 30, 40 for displaying a first period of time between a first reference administration time and the current time, and the first reference administration time being distinguished in that the medicament portion has not been taken by the first reference administration time.

Abstract: The invention relates to a new process for graphic visualization and diagnosis of thrombi as well as the use of particle suspensions for the production of contrast media for the visualization of thrombi with use of nuclear spin tomography.

Abstract: The present invention relates to iron-containing nanoparticles having a modular structure, their production, and their use for diagnostic and therapeutic purposes.

Abstract: The present invention relates to iron-containing nanoparticles having a modular structure, their production, and their use for diagnostic and therapeutic purposes. The nanoparticles according to the invention are characterized in that they consist of an iron-containing core, a primary coat (synthesis polymer), and a secondary coat (targeting polymer) and, optionally, of pharmaceutic adjuvants, pharmaceuticals, and/or adsorption mediators/enhancers.

Abstract: The present invention relates to iron-containing nanoparticles having a modular structure, their production, and their use for diagnostic and therapeutic purposes.

Abstract: The invention relates to a new process for graphic visualization and diagnosis of thrombi as well as the use of particle suspensions for the production of contrast media for the visualization of thrombi with use of nuclear spin tomography.

Abstract: Modular iron-containing nanoparticles are disclosed, as well as their production and use in diagnosis and therapy. The nanoparticles are characterised in that they have an iron-containing core, a primary coat (synthetic polymer) and a secondary coat (target polymer), and optional auxiliary pharmaceutical substances, pharmaceuticals and/or adsorption mediators.

Abstract: A water-soluble carboxypolysaccharide-magnetic iron oxide complex of small particle diameter composed of a water-soluble carboxypolysaccharide and a magnetic iron oxide having a core diameter ranging from about 2 to about 7 nm, wherein the total diameter ranges from about 10 to about 50 nm, the ratio of the total diameter to the core diameter is about 15 or less, and the T.sub.2 -relaxivity ranges from about 10 to about 150 (mM.sec).sup.-1. Said complex has low toxicity and small side effects and is useful in the fields of medical treatment, biology and engineering as an iron-supplementing agent, an X-ray contrast medium, an MRI contrast medium, a reagent for blood flow rate measurement, a carrier for drug administration, etc.

Abstract: The invention relates to nanocrystalline magnetic particles consisting of gnetic iron oxide core of Fe.sub.3 O.sub.4, gamma-Fe.sub.2 O.sub.3 or mixtures thereof and an envelope chemisorbed to said core, the method for preparation of these particles as well as the use thereof in medical diagnostics and/or therapy. The magnetic particles, according to the invention, are characterized by composition of the coating material of natural or synthetic glycosaminoglycans and/or their derivatives with molecular weights of 500 Da to 250,000 Da, if necessary, covalently cross-linked with appropriate cross-linking agents and/or modified by specific additives.